Development Pipeline

At Aethox we are utilising our expertise and know-how to develop a pipeline of solid tumour targeting small molecules which dramatically improve the treatment responses of both generic and licenced cancer treatments through in-house development and partnering opportunities.   

We are preparing to initiate our first-in-human Phase I trial for cancer with our lead clinical candidate KCL-HO-1i with a chemotherapeutic agent (programme ATX101).